NCT01995227View on ClinicalTrials.gov

An Individualized Anti-Cancer Vaccine Study in Patients With HCC

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2013

Primary Completion Date

February 28, 2018

Study Completion Date

July 31, 2018

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

AlloVax

Personalized anti-cancer vaccine

BIOLOGICAL

CRCL

Personalized anti-cancer vaccine

BIOLOGICAL

AlloStim

ID injections IV infusion

Trial Locations (1)

Unknown

Hebrew University-Hadassah Medical Center, Jerusalem

Sponsors
All Listed Sponsors
lead

Mirror Biologics, Inc.

INDUSTRY

NCT01995227 - An Individualized Anti-Cancer Vaccine Study in Patients With HCC | Biotech Hunter | Biotech Hunter